Literature DB >> 28607101

Positive- and Negative-Control Pathways by Blood Components for Intermedilysin Production in Streptococcus intermedius.

Toshifumi Tomoyasu1,2, Takahiro Yamasaki3, Shinya Chiba3, Shingo Kusaka3, Atsushi Tabata1, Robert A Whiley4, Hideaki Nagamune5.   

Abstract

Streptococcus intermedius is an opportunistic bacterial pathogen secreting a human-specific cytolysin called intermedilysin (ILY) as a major pathogenic factor. This bacterium can degrade glycans into monosaccharides using two glycosidases, multisubstrate glycosidase A (MsgA) and neuraminidase (NanA). Here, we detected a stronger hemolytic activity mediated by ILY when S. intermedius PC574 was cultured in fetal bovine serum (FBS) than when it was grown in the standard culture medium. FBS-cultured cells also showed higher MsgA and NanA activity, although overproduction of ILY in FBS was undetectable in mutants nanA-null and msgA-null. Addition of purified MsgA and NanA to the FBS resulted in a release of 2.8 mM galactose and 4.3 mM N-acetylneuraminic acid; these sugar concentrations were sufficient to upregulate the expression of ILY, MsgA, and NanA. Conversely, when strain PC574 was cultured in human plasma, no similar increase in hemolytic activity was observed. Moreover, addition of human plasma to the culture in FBS appeared to inhibit the stimulatory effect of FBS on ILY, MsgA, and NanA, although there were individual differences among the plasma samples. We confirmed that human plasma contains immunoglobulins that can neutralize ILY, MsgA, and NanA activities. In addition, human plasma had a neutralizing effect on cytotoxicity of S. intermedius toward HepG2 cells in FBS, and a higher concentration of human plasma was necessary to reduce the cytotoxicity of an ILY-high-producing strain than an ILY-low-producing strain. Overall, our data show that blood contains factors that stimulate and inhibit ILY expression and activity, which may affect pathogenicity of S. intermedius.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Streptococcus intermedius; blood components; gene expression; glycosidase; intermedilysin; pathogenicity

Mesh:

Substances:

Year:  2017        PMID: 28607101      PMCID: PMC5563582          DOI: 10.1128/IAI.00379-17

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  41 in total

Review 1.  Protein sorting to the cell wall envelope of Gram-positive bacteria.

Authors:  Hung Ton-That; Luciano A Marraffini; Olaf Schneewind
Journal:  Biochim Biophys Acta       Date:  2004-11-11

2.  Clinical significance of bacteremia involving the "Streptococcus milleri" group: 51 cases and review.

Authors:  F Bert; M Bariou-Lancelin; N Lambert-Zechovsky
Journal:  Clin Infect Dis       Date:  1998-08       Impact factor: 9.079

3.  Intermedilysin, a novel cytotoxin specific for human cells secreted by Streptococcus intermedius UNS46 isolated from a human liver abscess.

Authors:  H Nagamune; C Ohnishi; A Katsuura; K Fushitani; R A Whiley; A Tsuji; Y Matsuda
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

4.  Role of catabolite control protein A in the regulation of intermedilysin production by Streptococcus intermedius.

Authors:  Toshifumi Tomoyasu; Atsushi Tabata; Riki Hiroshima; Hidenori Imaki; Sachiko Masuda; Robert A Whiley; Joseph Aduse-Opoku; Ken Kikuchi; Keiichi Hiramatsu; Hideaki Nagamune
Journal:  Infect Immun       Date:  2010-07-12       Impact factor: 3.441

Review 5.  Culture-negative brain abscess with Streptococcus intermedius infection with diagnosis established by direct nucleotide sequence analysis of the 16s ribosomal RNA gene.

Authors:  Naoko Saito; Ayumi Hida; Yuri Koide; Tadasuke Ooka; Yaeko Ichikawa; Jun Shimizu; Akitake Mukasa; Hirofumi Nakatomi; Shuji Hatakeyama; Tetsuya Hayashi; Shoji Tsuji
Journal:  Intern Med       Date:  2012-01-15       Impact factor: 1.271

6.  LacR mutations are frequently observed in Streptococcus intermedius and are responsible for increased intermedilysin production and virulence.

Authors:  Toshifumi Tomoyasu; Hidenori Imaki; Sachiko Masuda; Ayumi Okamoto; Hyejin Kim; Richard D Waite; Robert A Whiley; Ken Kikuchi; Keiichi Hiramatsu; Atsushi Tabata; Hideaki Nagamune
Journal:  Infect Immun       Date:  2013-06-24       Impact factor: 3.441

7.  Characterization of the Lactococcus lactis lactose operon promoter: contribution of flanking sequences and LacR repressor to promoter activity.

Authors:  R J van Rooijen; M J Gasson; W M de Vos
Journal:  J Bacteriol       Date:  1992-04       Impact factor: 3.490

8.  LuxS and expression of virulence factors in Streptococcus intermedius.

Authors:  D Pecharki; F C Petersen; A Aa Scheie
Journal:  Oral Microbiol Immunol       Date:  2008-02

9.  Streptococcus intermedius, Streptococcus constellatus, and Streptococcus anginosus (the Streptococcus milleri group): association with different body sites and clinical infections.

Authors:  R A Whiley; D Beighton; T G Winstanley; H Y Fraser; J M Hardie
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

10.  Molecular mapping to species level of the tonsillar crypt microbiota associated with health and recurrent tonsillitis.

Authors:  Anders Jensen; Helena Fagö-Olsen; Christian Hjort Sørensen; Mogens Kilian
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

View more
  1 in total

Review 1.  From Normal Flora to Brain Abscesses: A Review of Streptococcus intermedius.

Authors:  Elio Issa; Tamara Salloum; Sima Tokajian
Journal:  Front Microbiol       Date:  2020-05-07       Impact factor: 5.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.